News
Hinge Health prices IPO at $32/share, valuing company at $3B. CEO Daniel Perez's firm to trade as HNGE on NYSE, raising ...
The FDA's Oncologic Drugs Advisory Committee on Wednesday voted 5 to 4 against UroGen’s mitomycin as an option for low-grade ...
The FDA said it is making 'enhancements' designed to help states develop programs for importing cheaper drugs from Canada.
BioNTech to invest £1B in UK R&D over 10 years, receives £129M government grant to build research centers and HQ in London, ...
Weill Cornell Medicine study shows cocaine vaccine triggers antibodies & reduces drug use in small trial, but effects modest.
Moderna pulls BLA for its Covid-flu shot: The company suggested on its most recent … Get free access to a limited ...
Self-guided mental health programs and digital therapeutics like Headspace, DaylightRx save money, while virtual therapy from Lyra, Talkspace costs more ...
Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...
Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...
Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according ...
Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.
The gene editing company CRISPR Therapeutics surprisingly struck a deal with China-based biotech Sirius Therapeutics to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results